Kevin Baillie, a former Netflix executive, filed a wrongful termination lawsuit against the company. He claims Netflix fired him from his $1.1 million position. This followed his disclosure of medically prescribed ketamine use for depression.
Baillie headed creative at Netflix's Eyeline Studios. He revealed the treatment during a corporate "trust exercise" in January 2026.
The lawsuit alleges Netflix investigated his disclosure, suggesting recreational drug use. A Netflix attorney later confirmed the ketamine therapy factored into his April 2026 dismissal. Baillie seeks compensatory and punitive damages, alleging unlawful termination based on a medical condition.